Default company panoramic image

Gel Repairer Ltd.

Gel Repairer developed a formulation with the potential to become one of the first drugs to cure severe Osteoarthritis.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP
  • Founded September 2013
  • Employees 1
  • Website

Company Summary

Gel Repairer is a biotech startup in Degenerative Joint Diseases which developed a formulation with the potential to become one of the first drugs to cure severe Osteoarthritis (OA). OA causes activity limitations to 22.4% of the elderly (over 65 years old) and to 11.8% of people in the age bracket 45-64. To date, the only available pharmaceutical treatments for Osteaorthritis are pain killers, whereas no drugs to cure the disease exist yet.


  • Default avatar
    Valerio Di Nicola

    Dr. Valerio di Nicola, CSO, got his PhD in Microsurgery at "La Sapienza" University in Rome, Italy and has been working on regenerative medicine since then. He recently published two articles on Current Ageing Science on joint self repair. He is consultant in General and Colorectal Surgery at Noble's Hospital in Braddan, Isle of Man.

  • Default avatar
    Luca Escoffier

    Luca Escoffier, CIO, is an expert in nano-biotech technology transfer and is collaborating on the subject with University of Washington, US, Waseda University of Tokyo, Japan, and University of Trieste, Italy. He has been CIO of several Italian startups and co-founded the HUB Trieste, a co-working space fostering social innovation.

  • Default avatar
    Leonardo Zangrando

    Leonardo Zangrando, CEO, is an expert in pharma/biotech licensing and sales strategy, and has worked with several global pharma companies on projects in licensing, sales and marketing strategy, sales-force training. In 2011-2012 he was COO at a tissue engineering startup where he experienced first-hand the regulatory process for advanced therapy medicinal products.